Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: NovoCure Limited

Market Cap 2.04B 1.76B 1.62B 1.52B 2.85B 193B 2.88B 19.12B 7.47B 94.34B 7.65B 7.49B 326B P/E Ratio 2026 *
-11x
P/E Ratio 2027 * -15x
Enterprise Value 1.82B 1.57B 1.44B 1.35B 2.54B 172B 2.56B 17.03B 6.65B 84.07B 6.82B 6.67B 291B EV / Sales 2026 *
2.58x
EV / Sales 2027 * 2.62x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day-1.01%
1 week+4.45%
Current month+3.29%
1 month+0.11%
3 months+45.94%
6 months+35.70%
Current year+36.12%
1 week 16.41
Extreme 16.41
18.35
1 month 14.84
Extreme 14.845
18.67
Current year 9.82
Extreme 9.82
18.92
1 year 9.82
Extreme 9.82
18.92
3 years 9.82
Extreme 9.82
45.21
5 years 9.82
Extreme 9.82
232.76
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 2025-11-30
Director of Finance/CFO 52 2024-12-31
Chief Tech/Sci/R&D Officer - 2023-01-16
Director TitleAgeSince
Chairman 63 2008-12-31
Director/Board Member 65 2011-08-04
Director/Board Member 69 2018-05-30
Date Insider Type Main position Quantity % Market Cap.
06-03Sell

Chief Executive Officer

-34,273 0.0296%
06-02Free

Director

28,609 0.0247%
06-02Free

Director

28,609 0.0247%
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%+4.45%+0.28%-59.91% 2.04B
-0.16%-0.58%+24.06%-5.93% 12.52B
+0.14%-5.02%+55.31%+23.86% 5.89B
-1.07%+0.96%+3.38%-23.06% 5.71B
+0.20%+3.22%-28.92%+17.99% 4.28B
-1.06%+0.81% - - 4.21B
+0.73%+3.36%-27.08%-23.45% 3.86B
-0.97%+8.33%+51.24%+223.28% 1.86B
+0.67%+0.17%+58.07%-4.91% 1.55B
+0.99%-2.00%-11.57%-50.19% 1.32B
Average -0.15%+2.24%+13.86%+10.85% 4.32B
Weighted average by Cap. -0.22%+1.12%+15.08%+3.62%

Financials

2026 *2027 *
Net sales 704M 607M 558M 524M 984M 66.53B 994M 6.6B 2.58B 32.58B 2.64B 2.59B 113B 777M 670M 617M 578M 1.09B 73.46B 1.1B 7.29B 2.85B 35.97B 2.92B 2.86B 124B
Net income -183M -158M -145M -136M -256M -17.32B -259M -1.72B -671M -8.48B -688M -673M -29.35B -133M -115M -106M -98.99M -186M -12.57B -188M -1.25B -487M -6.16B -499M -489M -21.3B
Net Debt -222M -191M -176M -165M -310M -20.98B -313M -2.08B -813M -10.27B -833M -815M -35.55B -
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
26-06-15 17.60 $ -1.01% 2,767,816
26-06-12 17.78 $ +0.40% 1,037,315
26-06-11 17.71 $ +6.37% 1,348,095
26-06-10 16.65 $ -3.42% 982,195
26-06-09 17.24 $ +2.31% 1,544,076
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
17.60USD
Average target price
26.29USD
Spread / Average Target
+49.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!